Showing 3471-3480 of 4082 results for "".
- Biofrontera Announces Restructuring of Supply Agreement, Reduces Ameluz Transfer Pricinghttps://practicaldermatology.com/news/biofrontera-inc-announces-private-placement-of-up-to-160-million-priced-at-market-per-nasdaq-rules/2462246/Biofrontera has announced a restructuring of agreements with its former parent company, Biofrontera AG, aimed at enhancing long-term profitability. As a result, the transfer price of its leading product, Ameluz, indicated for the treatment of actinic keratosis, will be slashed from 50% to 25% for
- Intravenous Ertapenem Shows Improvement in Hidradenitis Suppurativahttps://practicaldermatology.com/news/intravenous-ertapenem-for-hidradenitis-suppurativa-efficacy-and-patient-satisfaction/2462245/Results from a new analysis indicated that intravenous ertapenem was associated with improvements in markers of hidradenitis suppurativa (HS) and was linked with increased patient satisfaction. The retrospective analysis included medical records of 98 patients with HS who
- Six Dermatology Biotechs Combine to Form Alys Pharmaceuticalshttps://practicaldermatology.com/news/six-dermatology-biotechs-combine-to-form-alys-pharmaceuticals/2462241/Originating from the aggregation of six asset-centric dermatology companies, Alys Pharmaceuticals was launched with $100 million financing by Medicxi, a healthcare-focused investment firm. Alys combines the assets and platforms of Aldena Therapeutics, Graegis Pharma
- Ceramide and Niacinamide-Containing Moisturizer Safe, Effective with Topical Acne Treatmenthttps://practicaldermatology.com/news/study-reveals-ceramide-and-niacinamide-containing-moisturizer-enhances-topical-acne-treatment/2462234/New research suggests that a moisturizer containing ceramides and niacinamide (CCM) significantly improved lesions from acne vulgaris when combined with anti-acne medication. "Dermatologists often suggests using moisturizers for a wide range of skin problems initiated by acne
- Guselkumab Demonstrates Significant and Rapid Scalp Psoriasis Clearance in People of Colorhttps://practicaldermatology.com/news/tremfya-guselkumab-demonstrates-significant-and-rapid-scalp-psoriasis-clearance-in-people-of-color-in-new-large-phase-3b-study/2462218/At the Maui Derm Hawaii 2024 conference, Johnson & Johnson presented topline data from Cohort B in the Phase 3b VISIBLE study that demonstrated that TREMFYA® (guselkumab) showed rapid and significant clearance in moderate to severe scalp psoriasis (PsO) and significant improvement
- Upadacitinib Improves Night-time Itch and Sleep Disturbance: Studyhttps://practicaldermatology.com/news/analysis-upadacitinib-improves-night-time-itch-and-sleep-disturbance/2462217/Researchers publishing the poster at Maui Derm 2024 analyzed integrated data from the Measure Up 1 and Measure Up 2 phase-3 randomized, double-blinded studies looking the safety and efficacy of upadacitinib 15 mg (UPA 1
- Interim Analysis Shows Dupilumab Safe, Effective for AD Treatment at 2 Yearshttps://practicaldermatology.com/news/real-world-effectiveness-of-dupilumab-in-adult-and-adolescent-patients-with-atopic-dermatitis-2-year-interim-data-from-the-prose-registry/2462202/Dupilumab was associated with improved disease control in patients with moderate-to-severe atopic dermatitis (AD) at two years, according to a new interim analysis. The study, published in Dermatology and Therapy, examined two-year data from the PROSE AD Registry (an ongoing, pros
- Upadacitinib Linked with Improvement for Hand Eczema in Patients with Atopic Dermatitishttps://practicaldermatology.com/news/updacitinib-shows-promise-for-ad-and-hand-eczema-in-trial/2462198/Results from a new study suggest that upadacitinib is efficacious for the treatment of hand eczema (HE) and atopic dermatitis (AD) in patients with AD. The study authors, publishing in Contact Dermatitis, included a total of 38 patients in the observational cohort analysis (32 of
- Vidac Queues Up Phase 2b Study for Potential Actinic Keratosis Therapyhttps://practicaldermatology.com/news/vidac-pharma-to-conduct-phase-2b-study-for-actinic-keratosis-therapeutic-candidate-vda-1102-with-centroderm/2462192/Vidac Pharma Holdings recently announced the commencement of a Phase 2b trial for its candidate therapy (VDA-1102) to treat actinic keratosis (AK), and has engaged with a research team from a leading clinical dermatology clinical research institute (CentroDerm GmbH). According to the ma
- Study: Implementing a Treat-to-Target Approach Can Benefit PsA Patientshttps://practicaldermatology.com/news/implementation-of-the-treat-to-target-approach-in-psoriatic-arthritis-and-its-outcomes-in-routine-clinical-practice/2462181/A new study published in Cureus showed measuring disease activity with validated tools and treating to target (T2T) in patients with psoriatic arthritis (PsA) is crucial to improving quality of life and better disease control. The first-ever retrospective review from